QuellTX Logo
22/11/21

Quell Therapeutics Announces Participation in Upcoming Investor Conferences

London, UK and Boston, MA – November 22, 2021 – Quell Therapeutics Ltd (“Quell”), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will participate in two upcoming investor conferences:

  • Piper Sandler 33rd Annual Virtual Healthcare Conference

Format: On-Demand Presentation

Date: Monday, November 22, 2021

Time: 10:00 a.m. ET

  • Evercore ISI 4th Annual Health CONx Virtual Conference

Format: Fireside Chat

Date: Tuesday, November 30, 2021

Time: 1:25 – 1:45 p.m. ET

About Quell Therapeutics

Quell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies that aim to harness, direct and optimize their immune suppressive properties to address serious medical conditions driven by the immune system.

The Company is leveraging its pioneering phenotype lock technology, unique multi-modular platform and integrated manufacturing capabilities to design and develop a pipeline of highly engineered Treg cell therapies with greater potential for persistence, potency and stability than earlier generations of Treg cell therapy approaches.

Quell’s lead candidate QEL-001 is being developed to induce operational tolerance following liver transplantation, with the potential to protect the post-transplant liver without the need for chronic immunosuppressive medications. Quell is also advancing additional programs in neuroinflammatory and autoimmune diseases. www.quell-tx.com.

Contacts

Luke Henry, Chief Business Officer
Quell Therapeutics
IR@quell-tx.com

Media: Mark Swallow, Frazer Hall, Eleanor Perkin
MEDiSTRAVA Consulting
+44 207 638 9571
Quell-Tx@Medistrava.com

Investors: Christina Tartaglia
Stern Investor Relations, Inc.
+1 212 362 1200
christina@sternir.com

27/04/22

Quell Therapeutics and Cellistic™ enter a strategic collaboration to develop an iPSC-derived allogeneic T-regulatory (Treg) cell therapy platform

Collaboration combines Quell’s pioneering autologous multi-modular Treg cell therapy platform and Cellistic™’s expertise in iPSC cell therapy platform development and scale-upAims to accelerate the development of a next-generation allogeneic Treg platform that could open significant opportunities for Quell’s creation of…...

Read More
10/03/22

Quell Therapeutics Announces Presentation at Oppenheimer’s 32nd Annual Healthcare Conference

London, UK and Boston, MA, USA – March 10, 2022 – Quell Therapeutics Ltd (“Quell”), a world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will…...

Read More
06/01/22

Quell Therapeutics Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference

LONDON, UK and BOSTON, MA – January 6, 2022 – Quell Therapeutics Ltd (“Quell”), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will…...

Read More